In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $1.23 in the prior trading day, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $1.22, down -0.81%%. In other words, the price has decreased by -$0.81% from its previous closing price. On the day, 1.61 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ALLO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.71 and its Current Ratio is at 9.71. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.21.
On March 14, 2025, Citizens JMP Upgraded its rating to Mkt Outperform which previously was Mkt Perform but kept the price unchanged to $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 10 ’25 when MESSEMER DEBORAH M. sold 36,885 shares for $1.42 per share. The transaction valued at 52,377 led to the insider holds 107,431 shares of the business.
MESSEMER DEBORAH M. bought 36,885 shares of ALLO for $52,391 on Jun 10 ’25. On Apr 21 ’25, another insider, Yoshiyama Annie, who serves as the SVP, Finance of the company, sold 9,601 shares for $1.41 each. As a result, the insider received 13,537 and left with 130,663 shares of the company.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is -8.33%, while the 200-Day Moving Average is calculated to be -38.89%.
Shares Statistics:
A total of 218.60M shares are outstanding, with a floating share count of 149.51M. Insiders hold about 31.65% of the company’s shares, while institutions hold 66.02% stake in the company.
